Menu Search
Equities

Changchun BCHT Biotechnology Co

688276:SHH

Changchun BCHT Biotechnology Co

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)22.05
  • Today's Change-0.01 / -0.05%
  • Shares traded1.71m
  • 1 Year change-63.85%
  • Beta--
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Changchun BCHT Biotechnology Co grew revenues 70.30% from 1.07bn to 1.82bn while net income improved 175.98% from 181.54m to 501.01m.
Gross margin89.44%
Net profit margin27.99%
Operating margin32.03%
Return on assets11.03%
Return on equity13.62%
Return on investment13.51%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at Changchun BCHT Biotechnology Co fell by 425.06m. However, the company earned 255.21m from its operations for a Cash Flow Margin of 13.99%. In addition the company used 638.63m on investing activities and also paid 42.14m in financing cash flows.
Cash flow per share--
Price/Cash flow per share--
Book value per share9.96
Tangible book value per share9.14
More ▼

Balance sheet in CNYView more

Changchun BCHT Biotechnology Co uses little debt in its capital structure as supported by a debt to capital ratio of 2.52%.
Current ratio2.27
Quick ratio1.99
Total debt/total equity0.0259
Total debt/total capital0.0252
More ▼

Growth rates in CNY

Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items increased 175.98%. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
Div yield(5 year avg)0.13%
Div growth rate (5 year)--
Payout ratio (TTM)11.75%
EPS growth(5 years)31.37
EPS (TTM) vs
TTM 1 year ago		140.23
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.